Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemobiotech Inc.

This article was originally published in Start Up

Executive Summary

Hemobiotech Inc. was formed to commercialize HBOC technology originally developed at Texas Tech University. By modifying hemoglobin with ATP, glutathione and adenosine, the company claims it eliminates toxicity and vasoactivity. The company also has evidence that HemoTech may have the added benefit of inducing erythropoiesis.

You may also be interested in...



Artificial Blood: Finding the Formula for Approval

Despite decades of effort and more than $1 billion dollars invested in commercial blood substitute R&D, no products are approved for use in the US. Can next-generation companies succeed where so many others have failed?

Gloucester Pharmaceuticals Inc.

Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.

Hemocellular Therapeutics Inc.

Hemocellular Therapeutics Inc. hopes to extend the life of donated human platelets with proprietary freeze-drying technology. Its Stasix, now in preclinical development, is a powdered form of platelets that can be stored at room temperature indefinitely. Once rehydrated, full functionality is restored immediately. Furthermore, Hemocellular claims that since it removes protein plasma before freeze-drying, no cross-matching to patients is necessary.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090984

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel